How much cash does Rigel Pharmaceuticals generate?

Rigel Pharmaceuticals (RIGL) generated $79.3M in operating cash flow over the trailing twelve months.

Where does Rigel Pharmaceuticals's cash flow data come from?

Every line is extracted from Rigel Pharmaceuticals's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.

Rigel Pharmaceuticals RIGL Cash Flow Statement

Income Statement Balance Sheet Cash Flow Ratios Segments

Quarterly Annual TTM

YoY QoQ

Simplified Detailed

	TTM Q1 '26	TTM Q4 '25	TTM Q3 '25	TTM Q2 '25	TTM Q1 '25
Depreciation and amortization	$2.41M-0.3%	$2.42M-0.1%	$2.42M-0.3%	$2.43M-0.2%	$2.43M+9.2%
Stock-based compensation	$12.84M+1.0%	$12.71M+5.5%	$12.05M+6.3%	$11.33M+7.1%	$10.58M-14.6%
Deferred income taxes	——	——	——	——	$0—
Change in accounts receivable	$8.4M-17.2%	$10.15M-33.9%	$15.35M+39.5%	$11M-21.6%	$14.04M+26.8%
Change in inventories	——	——	——	$1.69M+138%	-$4.49M-487%
Change in accounts payable	——	——	——	$1.16M+122%	-$5.32M-39.9%
Change in accrued liabilities	——	——	——	——	——
Change in other assets	——	——	——	——	——
Change in operating lease liabilities	——	——	——	——	$511K+174%
Net cash from operating activities	$79.27M+4.8%	$75.66M+11.0%	$68.18M+3.6%	$65.83M+85.0%	$35.59M+13.1%
Acquisitions, net of cash acquired	——	$5M0.0%	$5M0.0%	$5M0.0%	$5M0.0%
Purchases of investments	$155.76M+1.5%	$153.49M+16.0%	$132.28M+64.1%	$80.6M+64.1%	$49.13M+39.3%
Proceeds from maturities/sales of investments	$65.97M+7.9%	$61.13M+12.5%	$54.33M+37.2%	$39.6M-6.9%	$42.55M+7.2%
Net cash from investing activities	-$89.79M+2.8%	-$92.37M—	——	——	——
Repurchases of common stock	——	——	——	——	——
Repayments of debt	——	——	——	——	$0—
Proceeds from issuance of common stock	$7.94M-2.0%	$8.1M+22.0%	$6.64M+163%	$2.53M+7.0%	$2.36M+20.1%
Net cash from financing activities	——	——	——	——	——
Net increase (decrease) in cash	——	——	——	——	$20.21M-15.6%
Interest paid	$6.24M-5.1%	$6.57M-2.7%	$6.76M-2.3%	$6.91M-1.3%	$7.01M-0.4%
Income taxes paid	——	$1.06M+20.8%	$880K+26.3%	$697K+35.6%	$514K+55.3%
Accrued research and development	——	——	——	——	——
Accrued compensation and employee benefits	——	——	——	——	——
Operating lease liabilities	——	——	——	——	$511K+174%
Accrued liabilities	——	——	——	——	$1.94M-61.2%
Increase (Decrease) in Prepaid Expense and Other Assets	——	——	——	——	——
Right-of-use assets	——	——	——	——	-$593K-196%
Investment Income Net Amortization Of Discount And Premium	$1.13M-1.7%	$1.15M-2.8%	$1.18M+50.7%	$785K+13.1%	$694K-2.1%
Revenue reserves and refund liability	——	——	$7.83M-28.5%	$10.96M-7.9%	$11.89M+10.5%
Payments to Acquire Short-Term Investments	$155.76M+1.5%	$153.49M+16.0%	$132.28M+64.1%	$80.6M+64.1%	$49.13M+39.3%
Proceeds from Maturities, Prepayments and Calls of Short-Term Investments	$65.97M+7.9%	$61.13M+12.5%	$54.33M+37.2%	$39.6M-6.9%	$42.55M+7.2%
Proceeds from exercises of stock options and other stock issuances	$7.94M-2.0%	$8.1M+22.0%	$6.64M+163%	$2.53M+7.0%	$2.36M+20.1%
Repayments of Long-Term Lines of Credit	——	——	——	——	$0—
Increase Decrease In Operating Lease Liability	——	——	——	——	$511K+174%
Accrued payables for stock repurchases, including applicable excise tax	——	——	——	——	——
Leased assets obtained in exchange for operating lease liabilities	——	——	——	——	$1.22M—
Income Taxes Paid, Net	——	$1.06M+20.8%	$880K+26.3%	$697K+35.6%	$514K+55.3%

Chart any of these lines over time, or line them up against competitors.

Compare these in charts →

Ask your AI about Rigel Pharmaceuticals.

Connect your AI assistant and get a quick read on the numbers, right in your chat.

Connect your AI

Claude

Questions, answered.

How much cash does Rigel Pharmaceuticals generate?: Rigel Pharmaceuticals (RIGL) generated $79.3M in operating cash flow over the trailing twelve months.
Where does Rigel Pharmaceuticals's cash flow data come from?: Every line is extracted from Rigel Pharmaceuticals's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.